Valneva And LimmaTech Forge Strategic Partnership To Fast-Track Development Of Leading Tetravalent Shigella Vaccine
Portfolio Pulse from Benzinga Newsdesk
Valneva and LimmaTech have entered a strategic partnership to accelerate the development of a tetravalent Shigella vaccine. Valneva gains an exclusive worldwide license for LimmaTech's S4V Shigella vaccine candidate, adding a Phase 2 clinical asset to its R&D pipeline. LimmaTech will receive an upfront payment, future milestone and royalty payments, and will collaborate on the clinical development through Phase 2.
August 01, 2024 | 5:58 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Valneva has secured an exclusive worldwide license for LimmaTech's S4V Shigella vaccine candidate, enhancing its R&D pipeline with a Phase 2 clinical asset. This partnership could accelerate Valneva's vaccine development and potentially lead to future revenue streams from milestone and royalty payments.
The partnership with LimmaTech provides Valneva with a promising Phase 2 clinical asset, which could accelerate its vaccine development efforts. The potential for future milestone and royalty payments adds a positive financial outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100